Lupin Launches Formoflo-G® MDI, World's First Triple Combination Drug For COPD In India
Mumbai: Lupin Limited on 6 October 2026 announced the launch of Formoflo-G® MDI, a fixed-dose triple combination metered-dose inhaler for the management of chronic obstructive pulmonary disease (COPD) in India. Regulatory Approval The launch follows approval from the Drug Controller General of India (DCGI), marking an expansion of treatment options for patients with COPD. Product Details Lupin…
Mumbai - On October 6th, 2026, Lupin Limited unveiled Formoflo-G® MDI, the first triple combination fixed-dose metered-dose inhaler for managing chronic obstructive pulmonary disease (COPD) in India. Approval from the Drug Controller General of India (DCGI) facilitated this addition to treatment options for patients struggling with COPD.
Lupin Formoflo-G® contains Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate, formulated for the long-term management of moderate to severe COPD with a twice-daily single-strength dose. This innovative drug fills a gap in the market, as stated by Nilesh Gupta, Lupin's Managing Director, who emphasized its potential to enhance patient outcomes.
Rajeev Sibal, President of India Region Formulations at Lupin, highlighted the new product's contribution to Lupin's respiratory therapy portfolio, providing healthcare professionals with a valuable tool for COPD management. Lupin currently holds the second position in the Indian respiratory therapy segment, as per IQVIA's MAT March 2026 data.
COPD affects more than 5.5 crore individuals in India, making it a leading cause of mortality and disability in the country. This launch is poised to offer hope to these patients, as Lupin continues to fortify its leadership in respiratory care.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.